A Phase II Trial of Radiation Plus Temozolomide Followed by Adjuvant Temozolomide and Poly-ICLC in Patients With Newly Diagnosed Glioblastoma Multiforme.

Trial Profile

A Phase II Trial of Radiation Plus Temozolomide Followed by Adjuvant Temozolomide and Poly-ICLC in Patients With Newly Diagnosed Glioblastoma Multiforme.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2012

At a glance

  • Drugs Poly ICLC (Primary) ; Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 May 2012 Actual patient number is 97 according to ClinicalTrials.gov.
    • 02 May 2012 Actual end date changed from Aug 2009 to Apr 2010 as reported by ClinicalTrials.gov.
    • 15 Jul 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top